-

Tempus Introduces Workspaces into its Lens Data Analytics Platform

Lens is trusted by nearly 100 institutions to uncover novel insights

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, is broadly introducing its new Workspaces feature in the Lens platform. Workspaces is a private, coding-based cloud environment designed to unblock research and accelerate innovation. This new interface provides researchers a frictionless workflow for surfacing critical insights to power scientific discovery and development.

Lens is already trusted by nearly 100 institutions, including healthcare systems and biopharma companies, to power research that improves patient outcomes. Lens provides access to more than 200 petabytes of de-identified multimodal datasets, as well as a suite of tools that enable rapid time-to-insight, flexible analyses, and collaboration. In addition to Workspaces, other new features include the integration of Tempus One, an AI assistant that makes the vast amounts of data more accessible, and Cohort Builder, which helps define cohorts of interest by leveraging the platform’s rich molecular and clinical filters, including, cancer diagnosis, HLA genotype, comorbidities and more.

The new Workspaces feature enables users to easily leverage virtual machines designed to support a variety of research goals, query and analyze data directly in popular coding languages like python and R, and run tailored analyses using Tempus’s library of analytic templates. The flexibility it provides is the perfect complement to Lens’ other pre-built visualization tools that allow for faster time-to-insight and understand demographics, distribution, and prevalence across cohorts of interest.

“We’ve heavily invested in designing Lens to be the most seamless and fastest way to translate multimodal data into pivotal insights, and we’re proud that many institutions already rely on it for their research needs,” said Ryan Fukushima, Chief Operating Officer at Tempus. “Workspaces is flexible and fast, offering multiple virtual machine types to support diverse analytical needs and rapidly surface critical insights that can shape the future of oncology care."

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Tempus


Release Versions

Contacts

Social Media Profiles
More News From Tempus

Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:30 AM ET. The live webcast will be available through the events page of Tempus’ Investor Relations website or by clicking the following link: https://ev...

Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and being run in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, nonprofit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL), marking Tempus’ first study collaboration with a non-pr...

Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National Harbor, Maryland. “We’re excited to join the oncology community at this year’s meeting and highlight our latest research and...
Back to Newsroom